Purpose <p>This study aimed to compare a high (HBF) and low (LBF) bicarbonate (HCO<sub>3</sub><sup>−</sup>) replacement fluid over 96&#xa0;h after continuous veno-venous hemofiltration (CVVH) initiation using regional citrate anticoagulation to determine which fluid achieved better acid–base balance.</p> Methods <p>In this prospective, randomized, controlled, open-label, cross-over, single-center trial, patients were randomized to initially receive either LBF (22&#xa0;mmol/l HCO<sub>3</sub><sup>−</sup>) or HBF (30&#xa0;mmol/l HCO<sub>3</sub><sup>−</sup>) for 48&#xa0;h (first phase), followed by changing to the other fluid for a further 48&#xa0;h (second phase). Intracorporeal pH and HCO<sub>3</sub><sup>−</sup> changes were analyzed by calculating the rates of levels outside the standard values (excursion rates). Generalized estimating equations were performed to estimate the odds ratios for at least one pH/HCO<sub>3</sub><sup>−</sup> excursion. Time to normalization within the first phase for pH and HCO<sub>3</sub><sup>−</sup> was assessed using Kaplan–Meier curves and log-rank tests.</p> Results <p>A total of 88 patients were included. The rates for at least one pH and HCO<sub>3</sub><sup>−</sup> excursion were higher in patients treated with HBF compared to LBF (pH: first phase 52% vs. 41%; second phase 48% vs. 34%; HCO<sub>3</sub><sup>−</sup>: first phase 68% vs. 43%; second phase 73% vs. 43%). Adjusted odds ratios were 1.78 (95% CI 1.12–2.82; <i>p</i> = 0.015) for pH and 3.60 (95% CI 2.16–5.99; <i>p</i> &lt; 0.001) for HCO<sub>3</sub><sup>−</sup>. The time to normalization of pH in acidotic patients and of HCO<sub>3</sub><sup>−</sup> in patients with low HCO<sub>3</sub><sup>−</sup> did not differ significantly between HBF and LBF (<i>p</i> = 0.102, <i>p</i> = 0.468).</p> Conclusion <p>LBF showed significantly lower rates of pH and HCO<sub>3</sub><sup>−</sup> excursions compared to HBF and no significant differences to the pH normalization in acidotic patients were observed.</p> ClinicalTrials.gov-identifier <p>NCT04071171.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Comparison of two different bicarbonate replacement fluids during CVVH with RCA: a prospective, randomized, controlled trial

  • Fabian Perschinka,
  • Paul Köglberger,
  • Andrea Köhler,
  • Georg Franz Lehner,
  • Andreas Peer,
  • Sarah Maier,
  • Hanno Ulmer,
  • Romuald Bellmann,
  • Lui G. Forni,
  • Michael Joannidis

摘要

Purpose

This study aimed to compare a high (HBF) and low (LBF) bicarbonate (HCO3) replacement fluid over 96 h after continuous veno-venous hemofiltration (CVVH) initiation using regional citrate anticoagulation to determine which fluid achieved better acid–base balance.

Methods

In this prospective, randomized, controlled, open-label, cross-over, single-center trial, patients were randomized to initially receive either LBF (22 mmol/l HCO3) or HBF (30 mmol/l HCO3) for 48 h (first phase), followed by changing to the other fluid for a further 48 h (second phase). Intracorporeal pH and HCO3 changes were analyzed by calculating the rates of levels outside the standard values (excursion rates). Generalized estimating equations were performed to estimate the odds ratios for at least one pH/HCO3 excursion. Time to normalization within the first phase for pH and HCO3 was assessed using Kaplan–Meier curves and log-rank tests.

Results

A total of 88 patients were included. The rates for at least one pH and HCO3 excursion were higher in patients treated with HBF compared to LBF (pH: first phase 52% vs. 41%; second phase 48% vs. 34%; HCO3: first phase 68% vs. 43%; second phase 73% vs. 43%). Adjusted odds ratios were 1.78 (95% CI 1.12–2.82; p = 0.015) for pH and 3.60 (95% CI 2.16–5.99; p < 0.001) for HCO3. The time to normalization of pH in acidotic patients and of HCO3 in patients with low HCO3 did not differ significantly between HBF and LBF (p = 0.102, p = 0.468).

Conclusion

LBF showed significantly lower rates of pH and HCO3 excursions compared to HBF and no significant differences to the pH normalization in acidotic patients were observed.

ClinicalTrials.gov-identifier

NCT04071171.